Quantum computing (QC) is expected to revolutionize drug research by performing tasks classical supercomputers are not capable of. However, practically useful quantum computation is not yet a reality, and thus it is still unclear when and whether QC will be capable of solving real-world issues in drug discovery. By identifying the QC-related activities of pharmaceutical companies, startups, and academia in the field of drug discovery and development, we show that QC has gained traction across all of these stakeholder groups, that there is focus on developing utilities related to lead optimization and compound screening, and that there is a need for collaboration in the highly dynamic QC ecosystem.

量子计算 (QC) 有望通过执行经典超级计算机无法完成的任务来彻底改变药物研究。然而，实际有用的量子计算尚未成为现实，因此尚不清楚 QC 何时以及是否能够解决药物发现中的现实问题。通过确定制药公司、初创公司和学术界在药物发现和开发领域的 QC 相关活动，我们表明 QC 已经在所有这些利益相关者群体中获得了关注，重点是开发与先导优化和相关的实用程序化合物筛选，并且需要在高度动态的 QC 生态系统中进行协作。